Drug Overview

Selicrelumab is a highly advanced, experimental medicine designed to help the human body fight cancer. It is created in a laboratory and belongs to a modern group of treatments that boost the immune system. Because it is still being carefully studied and tested by researchers, it is not available at a normal local pharmacy. Patients can only receive this medicine if they are taking part in approved medical research studies, also known as clinical trials.

• Generic name: Selicrelumab (also known in research as RG7876 or RO7049665)
• US Brand names: None (Investigational drug)
• Drug Class: CD40 agonist, Monoclonal antibody
• Route of Administration: Intravenous (IV) infusion (given directly into a vein)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Selicrelumab is a powerful Immunotherapy and possesses Targeted Therapy characteristics. Unlike traditional chemotherapy that acts like a poison to kill all fast-growing cells, this medicine acts like an alarm bell to wake up your body’s natural defense system.

To understand how it works at the molecular level, you must look at how cancer hides. Normally, your body has scout cells (called dendritic cells and macrophages) that patrol for diseases. These scout cells have a special receiver button on their surface called CD40. When cancer starts to grow, it often puts the immune system to sleep so the scout cells ignore the tumor.

Selicrelumab is an antibody designed to find and press that CD40 button. When the drug binds to the CD40 receiver, it sends a strong emergency signal deep inside the scout cells. This wakes them up. The activated scout cells then present pieces of the cancer to the T-cells (the hunter cells of the immune system). This process trains a massive army of T-cells to specifically seek out and destroy the cancer cells, no matter where they are hiding in the body.

FDA-Approved Clinical Indications

Because this medicine is still classified as an investigational drug, it does not have official FDA-approved uses for the general public yet. However, it is being tested in clinical trials for the following areas:

Oncological uses

• Investigational treatment for advanced solid tumors, such as melanoma (skin cancer) and pancreatic cancer.
• Investigational treatment for advanced colorectal cancer.
• Investigational treatment for certain types of lymphomas.

Non-oncological

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Because selicrelumab is an experimental therapy, the exact amount a patient receives depends entirely on the strict rules of their specific clinical trial. It is often tested on its own, or combined with other immunotherapy drugs to make it work better. The table below outlines the standard dosing framework observed in recent Phase 1 human research studies.

Dose Adjustments:

Because this medicine stimulates the immune system, it can sometimes cause inflammation in healthy organs like the liver. If routine blood tests reveal an increase in liver enzymes, the clinical trial doctors will pause the medication until the liver heals. Patients with severe hepatic (liver) insufficiency or renal (kidney) insufficiency may not be allowed to join certain trials to protect their organ health.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have provided important information on how well selicrelumab works. Because the drug is still in the early phases of testing (Phase 1 and Phase 1b), massive survival rate numbers are not fully established yet.

Instead, researchers have focused on proving the drug is safe and active. In recent trials where selicrelumab was given to patients with heavily pretreated advanced solid tumors, the drug successfully activated the immune system, which was proven by blood tests showing higher numbers of active T-cells. While tumor shrinkage (objective response rate) remained modest when the drug was used completely on its own (often ranging between 5 to 15 percent in advanced cases), researchers found that it works much better as a team player. Recent 2024 and 2025 data show that combining selicrelumab with other immune-boosting drugs, like atezolizumab, helps extend the time before the disease progresses in patients who have run out of other treatment options.

Safety Profile and Side Effects

Like all medicines that boost the immune system, selicrelumab can cause side effects. Because the immune system is working harder, it can sometimes cause symptoms that feel like a severe flu or mistakenly attack healthy parts of the body.

Black Box Warning:

Because this drug is investigational and not available on the open market, it does not currently carry an official FDA Black Box Warning.

Common side effects

These side effects have been reported in greater than 10 percent of patients during clinical trials:

• Fever and chills (often happening on the day of the infusion)
• Feeling extremely tired or weak (fatigue)
• Nausea and decreased appetite
• Mild increases in liver enzymes (discovered during routine blood tests)
• Cytokine release syndrome (a temporary immune reaction that causes flu-like symptoms)

Serious adverse events:

• Severe Cytokine Release Syndrome that causes dangerous drops in blood pressure and trouble breathing.
• Immune-mediated hepatitis (severe liver inflammation that can damage the organ).
• Immune-mediated inflammation in other organs, such as the lungs or intestines.

Management strategies:

Patient safety relies on careful monitoring. To prevent infusion reactions, doctors often give patients pre-medications like acetaminophen and antihistamines before the IV drip begins. If a patient develops a high fever or low blood pressure during the infusion, the nurses will immediately slow down or stop the medicine. If there are signs of serious immune system overactivity (like severe liver stress), the doctor will pause the selicrelumab and give the patient strong steroid medications to calm the immune system down.

Research Areas:

While selicrelumab is not currently used directly with stem cell transplants, it plays a massive role in tumor microenvironment research. Tumors build a protective wall around themselves to keep the immune system out. Research shows that stimulating the CD40 receptor helps break down this wall. Scientists are studying how using selicrelumab to break down the tumor’s shield might make future regenerative cell therapies and cancer vaccines much more effective at destroying hidden cancer cells.

Patient Management and Practical Recommendations

Participating in a clinical trial for an experimental immunotherapy requires strict teamwork between the patient and the healthcare team.

Pre-treatment tests to be performed:

• A complete blood count test to check the health of red and white blood cells before treatment starts.
• Comprehensive metabolic panels to ensure the liver and kidneys are working perfectly.
• A physical exam and vital signs check to establish a baseline for blood pressure and heart rate.

Precautions during treatment:

Patients must listen very closely to their bodies. Because immune-mediated side effects can happen anywhere in the body, any sudden change in how a patient feels must be reported. Side effects from immunotherapy can happen during the infusion, a few days later, or even weeks after the dose was given.

Do’s and Don’ts list:

• Do call your clinical trial doctor immediately if you develop a fever, chills, a new cough, or severe diarrhea.
• Do keep all your appointments for routine blood tests, as these tests can catch liver problems before you even feel sick.
• Do drink plenty of water and get plenty of rest on the days you receive your infusion.
• Don’t ignore extreme tiredness or sudden yellowing of your eyes, as these can be signs of organ stress.
• Don’t take over-the-counter pain medicines, fever reducers, vitamins, or herbal supplements without asking your oncology team first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Selicrelumab is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.